This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
5 Citations 13 Q&As
10 Citations 13 Q&As
Facts about Lipopolysaccharide-binding protein.
Acts as an affinity enhancer for CD14, facilitating its association with LPS. Promotes the release of cytokines in response to bacterial lipopolysaccharide (PubMed:7517398, PubMed:24120359).
Human | |
---|---|
Gene Name: | LBP |
Uniprot: | P18428 |
Entrez: | 3929 |
Belongs to: |
---|
BPI/LBP/Plunc superfamily |
LBP; lipopolysaccharide binding protein; lipopolysaccharide-binding protein; LPS-binding protein; MGC22233
Mass (kDA):
53.384 kDA
Human | |
---|---|
Location: | 20q11.23 |
Sequence: | 20; NC_000020.11 (38346482..38377013) |
Detected in blood serum (at protein level).
Secreted. Cytoplasmic granule membrane. Membrane-associated in polymorphonuclear Leukocytes (PMN) granules.
The Boster Microplate Reader is a flexible instrument for measuring the absorbance the aqueous solution. You can use it for small samples (0.5 ul), and large samples (up to 1 ml). For large sample volumes you must use a multichannel pipette. The company provides credits for products, which you can use to share your results with other users. For more details, go to Boster Bio: Best uses for the LBP Marker
Despite its low diagnostic accuracy however, the LBP marker has many advantages over other diagnostic tests for the lower back pain. The LBP marker can be used to distinguish those suffering from pathological conditions. Its high sensitivity value and specificity allow it to identify subclinical risk of atherosclerosis. The marker can also be used to determine the risk of developing atherosclerosis.
LBP has been studied in connection with liver disease, which is associated with higher mortality rates. Additionally, it has been utilized to predict the outcome of lung cancer and HCV treatment. It is a useful marker in clinical research as it is associated with many illnesses and their complications. Its clinical significance has made LBP an essential tool in numerous studies. Therefore, it is crucial to explore the potential of the LBP marker in future studies.
There are many options for the LBP marker that include the LBP -P. The markers MT–P are a better option than the MT–P–P–B marker. This marker is not yet widely employed in clinical practice. The positive relationship between CRP and this marker is not clear. This marker is not associated with age. Therefore, it is essential to determine whether LBP is linked to the risk of inflammatory conditions.
LBP levels in human samples vary from 5 to 15 ug/ml. The LBP levels in bovines are 0.05 to 2.5 ug/ml. This is why it is essential to select the right concentration for the human sample. The LBP marker can be dilute to 1:800. The ELISA kit comes with the possibility of a dilution of 3:10-800.
Chronic LBP is a common medical condition that can result in significant personal and financial pain and suffering. It can happen in many different circumstances and can vary in severity over time. LBP is typically subacute and lasts for less than six weeks. Chronic LBP however, on the contrary the other hand, is more persistent and reoccurs over time. In both instances, there are a number of characteristics that define the symptoms of chronic LBP. Both cases are treated using the combination of medications and other therapies.
Low back pain (LBP), is a major global issue. According to research, it is the number one cause of absenteeism and the second most common reason for disability among younger people. It is also the third most frequently cited reason for admission to hospitals and operations. The back pain of the low back is responsible for 12.5 percent of all sick days in the UK. It is the primary reason for working absences. There is no known cure for chronic LBP however there are treatments available.
The study's authors assessed the effects of e-health interventions upon chronic LBP symptoms of patients suffering from back pain that is low in the back. E-health interventions were equally effective as face-to-face interventions when it came to improving functional status specific to the back. Two independent reviewers were utilized to evaluate the quality of the studies. They calculated the risk of bias and extracted data from the studies. The 95% confidence interval (95%CI) and standardized mean differences were used to calculate the effect size.
Certain studies showed positive effects of PNF in pulmonary function in chronic LBP patients. However the authors did not examine all studies and only one pulmonary function indicator was used. The results may have been biased because they did not include all studies. Evidence-based medicine studies suggest that PNF training is more effective for chronic LBP than traditional treatments. The review assessed the effects of PNF on balance, pain and pulmonary function in chronic LBP patients.
The LBP Marker is an acute phase reaction marker that is not a diagnostic of SIRS. The disorder is caused by severe stimulation of the immune system such as infection. Noninfectious insults, such as trauma and burns, could trigger sepsis. The progress and development of sepsis is closely linked to immunepathogenetic causes. The LBP marker could be useful in the early diagnosis and prognosis for sepsis.
Normal conditions show an average serum LPB level of 5 to 15 mg/dL. However, during acute phase responses this level may rise multiple times. In this context it is crucial to comprehend the significance of the LBP marker in Boster Bio. The level of this protein during the acute phase reaction is an indicator of the immune response. The LPB amount increases by 10 times.
It was found that both LBP and the BPI were involved with the development of an immune system for crassostrea Gigas. The animals are home to a variety of microbiome communities on their surfaces and within their bodies including their hemolymph as well as internal cavities. They have a robust immune system and a wide range of endobios. LBP from Gram-negative bacteria plays an essential roles in their interactions with and interactions with bosters.
LBP plays a significant role in the immune response to infections since it controls the movement of LPS monomers. Furthermore, LBP acts as a Lipid exchange protein, which assists in the binding of LPS to CD14 cell membrane molecule. The proinflammatory cytokines are released when LBP is bound to CD14. This can be related to activation of monocyte/macrophage systems cells.
The LBP Marker in Boster Bio has many applications in the treatment of cancer. Its antisense-riboprobe detected Cgbpi transcripts. This marker is a good choice for patients with cancer to aid in the development of treatments. The LBP Marker in Boster Bio will help doctors determine whether or not an individual type of cancer has spread.
Boster Bio's LBP Marker can aid researchers and clinicians better understand LBP in the body. In the past, research has found that high LBP is associated with an increased risk of death. However the study was limited to one patient with high LBP. In a subsequent study, the same LBP level was used to predict mortality. In multivariate analysis, however, the predictive value of high LBP was only limited to mortality. The LBP marker in Boster Bio was found to be significantly associated with the risk of cardiovascular disease in both the healthy and the sick population.
PMID: 2402637 by Schumann R.R., et al. Structure and function of lipopolysaccharide binding protein.
PMID: 7517398 by Wilde C.G., et al. Bactericidal/permeability-increasing protein and lipopolysaccharide (LPS)-binding protein. LPS binding properties and effects on LPS- mediated cell activation.
*More publications can be found for each product on its corresponding product page